@article{fdi:010073859,
  title = {{M}olecular analysis of pyrazinamide resistance in {M}ycobacterium tuberculosis in {V}ietnam highlights the high rate of pyrazinamide resistance-associated mutations in clinical isolates},
  author = {{N}guyen {Q}uang {H}uy and {C}ontamin, {L}. and {T}ran {T}hi {T}hanh {H}oa and {N}guyen {V}an {H}ung and {N}guyen {T}hi {N}goc {L}an and {N}guyen {T}hai {S}on and {N}guyen {V}iet {N}hung and {D}ang {D}uc {A}nh and {B}añuls, {A}nne-{L}aure and {N}guyen {T}hi {V}an {A}nh},
  editor = {},
  language = {{ENG}},
  abstract = {{P}yrazinamide ({PZA}) is a key antibiotic in current anti-tuberculosis regimens. {A}lthough the {WHO} has stressed the urgent need to obtain data on {PZA} resistance, in high tuberculosis burden countries, little is known about the level of {PZA} resistance, the genetic basis of such resistance or its link with {M}ycobacterium tuberculosis families. {I}n this context, this study assessed {PZA} resistance through the molecular analysis of 260 {V}ietnamese {M}. tuberculosis isolates. {F}irst-line drug susceptibility testing, pnc{A} gene sequencing, spoligotyping and mycobacterial interspersed repetitive units-variable number of tandem repeats ({MIRU}-{VNTR}) typing were performed. {O}verall, the pnc{A} mutation frequency was 38.1% (99 out of 260 isolates) but was higher than 72% (89 out of 123 isolates) in multidrug and quadruple-drug resistant isolates. {M}any different pnc{A} mutations (71 types) were detected, of which 55 have been previously described and 50 were linked to {PZA} resistance. {A}mong the 16 novel mutations, 14 are likely to be linked to {PZA} resistance because of their mutation types or codon positions. {G}enotype analysis revealed that {PZA} resistance can emerge in any {M}. tuberculosis cluster or family, although the mutation frequency was the highest in {B}eijing family isolates (47.7%, 62 out of 130 isolates). {T}hese data highlight the high rate of {PZA} resistance-associated mutations in {M}. tuberculosis clinical isolates in {V}ietnam and bring into question the use of {PZA} for current and future treatment regimens of multidrug-resistant tuberculosis without {PZA} resistance testing.},
  keywords = {{VIET} {NAM}},
  booktitle = {},
  journal = {{E}merging {M}icrobes and {I}nfections},
  volume = {6},
  numero = {},
  pages = {art. no e86 [7 ]},
  ISSN = {2222-1751},
  year = {2017},
  DOI = {10.1038/emi.2017.73},
  URL = {https://www.documentation.ird.fr/hor/fdi:010073859},
}